Thyroglobulin peptide-MHC complex

The **thyroglobulin peptide-MHC complex** is formed when peptides generated from the proteolysis of thyroglobulin, a large glycoprotein produced by the thyroid gland, bind to major histocompatibility complex (MHC) molecules—most commonly MHC class II (HLA-DR, HLA-DQ in humans). These complexes are displayed on the surface of antigen-presenting cells and play a central role in immune surveillance and the initiation of autoimmune responses, particularly in thyroid autoimmunity. Upon presentation, thyroglobulin peptides can be recognized by T cell receptors on CD4+ T lymphocytes, leading to an immune response that underlies diseases such as Hashimoto’s thyroiditis and Graves’ disease[7][8]. Although not a traditional drug target, it is a central immunological target in autoimmune thyroid disorders.

Other names

Thyroglobulin peptide–HLA complexTG peptide–MHC complexTG-derived peptide–MHC class II complex

Antigen presentation: TG-derived peptides are presented by MHC class II molecules to CD4+ T cells, leading to immune activation. In autoimmunity, this leads to breakdown of self-tolerance and pathogenesis of thyroid autoimmune diseases.